Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis C and hepatocellular carcinoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Chronic hepatitis C infection (HCV) accounts for approximately 50% of the cases of hepatocellular carcinoma (HCC) in the United States. Cirrhosis or an advanced stage of fibrosis is the major risk factor of HCC; patients with cirrhosis are recommended to undergo surveillance with alpha-fetoprotein and ultrasound. Alpha interferon (IFN-α) is associated with a reduced risk of HCC in patients with chronic infection but insufficient data exist to recommend treatment of patients with cirrhosis and HCV for this reason alone. Resection and liver transplantation are the only ”curative” therapies available. Advanced fibrosis or cirrhosis in patients with HCC limits the number of patients for whom resection is applicable. Moreover, the remaining liver is at high risk of developing a second primary tumor. Partial hepatic resection for hepatocellular carcinoma should be restricted to patients with well-compensated cirrhosis (Child’s A class). Acceptable parameters include a single lesion not exceeding 5 cm, normal levels of bilirubin, and absence of portal hypertension. Liver transplantation is the best definitive treatment for HCV-infected patients who have small, localized HCC (solitary lesion not greater than 5 cm, or no more than 3 lesions, none of which are greater than 3 cm). Limitations of liver transplantation as a therapy for HCC are the scarcity of donor organs and the prolonged waiting time during which continued tumor growth occurs. Living donors can reduce waiting time and increase the number of patients treatable by transplantation. Chemoembolization and local ablation therapies have not been shown to confer survival benefits as primary treatments for HCC. The potential benefit of these procedures in controlling tumor growth to “bridge” patients to liver transplantation must be further investigated. Similarly, systemic chemotherapy and hormonal therapy do not generally produce a survival advantage. However, recent studies that used octreotide and combination doxorubicin/cisplatin/ 5-FU/interferon appear to be promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Alter M, Kruszon-Moran D, Nainan O, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562. Based upon data from NHANES III, this study describes the prevalence, racial and gender distribution of HCV in the general population.

    Article  PubMed  CAS  Google Scholar 

  2. Seeff L, Hollinger F, Alter H, et al.: Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 32:455–463.

    Article  Google Scholar 

  3. Kenny-Walsh E, Irish Hepatology Research Group: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999, 340:1228–1233.

    Article  Google Scholar 

  4. Hu K, Tong M: The long-term outcome of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999, 29:1311–1316.

    Article  PubMed  CAS  Google Scholar 

  5. Serfaty L, Aumaitre H, Chazouilleres O, et al.: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998, 27:1435–1440.

    Article  PubMed  CAS  Google Scholar 

  6. Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463–472.

    Article  PubMed  CAS  Google Scholar 

  7. Khan MF, Farrell GC, Byth K, et al.: Which patients with hepatitis C develop liver complications? Hepatology 2000, 31:513–520.

    Article  PubMed  CAS  Google Scholar 

  8. Bernardinello E, Cavalletto L, Chemello L, et al.: Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999, 46:3216–3222.

    PubMed  CAS  Google Scholar 

  9. Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347–354.

    Article  PubMed  CAS  Google Scholar 

  10. Niederau C, Lange S, Heintges T, et al.: Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687–1695. Frequently cited reference and one of the few prospective studies of the natural history of HCV-associated cirrhosis.

    Article  PubMed  CAS  Google Scholar 

  11. Aizawa Y, Shibamoto Y, Takagi I, et al.: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000, 89:53–59.

    Article  PubMed  CAS  Google Scholar 

  12. Benvegnu L, Pontisso P, Cavalletto D, et al.: Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997, 25:211–125.

    Article  PubMed  CAS  Google Scholar 

  13. Benvegnu L, Fattovich G, Noventa F, et al.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994, 74:2442–2448.

    Article  PubMed  CAS  Google Scholar 

  14. Bruno S, Silini E, Crosignani A, et al.: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997, 25:754–758.

    Article  PubMed  CAS  Google Scholar 

  15. Fattovich G, Giustina G, Degos F, et al.: Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997, 27:201–205.

    Article  PubMed  CAS  Google Scholar 

  16. Valla D, Chevallier M, Marcellin P, et al.: Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999, 29:180–185.

    Article  Google Scholar 

  17. Howell C, Jeffers L, Hoofnagle J: Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000, 119:1385–1396.

    Article  PubMed  CAS  Google Scholar 

  18. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998, 27:273–278. Review of the issues surrounding hepatocellular carcinoma screening in patients with viral hepatitis.

    Article  PubMed  CAS  Google Scholar 

  19. Tong M, Blatt L, Kao V: Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001, 16:553–559.

    Article  PubMed  CAS  Google Scholar 

  20. Aguayo A, Patt Y: Nonsurgical treatment of hepatocellular carcinoma. Clin Liver Dis 2001, 5:175–189.

    Article  PubMed  CAS  Google Scholar 

  21. Cottone M, Turri M, Caltagirone M, et al.: Screening for hepatocellular carcinoma in patients with Child’s A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994, 21:1029–1034.

    Article  PubMed  CAS  Google Scholar 

  22. Columbo M, De Franchis R, Del Ninno E, et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675–680.

    Article  Google Scholar 

  23. Peterson M, Baron R: Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001, 5:123–144. Detailed review of the performance characteristics of current radiologic modalities used to diagnosis and stage HCC.

    Article  PubMed  CAS  Google Scholar 

  24. Kim S, Lim H, Lee W, et al.: Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000, 25:246–250.

    Article  PubMed  CAS  Google Scholar 

  25. Donato F, Tagger A, Chiesa R, et al.: Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997, 26:579–584.

    Article  PubMed  CAS  Google Scholar 

  26. Fasani P, Sangiovanni A, De Fazio C, et al.: High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999, 29:1704–1707.

    Article  PubMed  CAS  Google Scholar 

  27. Mandishona E, MacPhail P, Gordeuk V, et al.: Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998, 27:1563–1566.

    Article  PubMed  CAS  Google Scholar 

  28. Baffis V, Shrier I, Sherker A, Szilagyi A: Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999, 131:696–701. Critical and comprehensive review of all the published studies written about the role of interferon alpha treatment in reducing HCC risk.

    PubMed  CAS  Google Scholar 

  29. Kubo S, Nishiguchi S, Hirohashi K, et al.: Effects of long-term postoperative interferon-a therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001, 134:963–967.

    PubMed  CAS  Google Scholar 

  30. Koff R: Cost-effectiveness of treatment for chronic hepatitis C. J Hepatol 1999, 31(Suppl 1):255–258.

    Article  PubMed  Google Scholar 

  31. Dusheiko G, Roberts J: Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995, 22:1863–1873.

    PubMed  CAS  Google Scholar 

  32. Bergsland E, Venook A: Hepatocellular carcinoma. Curr Opin Oncol 2000, 12:357–361.

    Article  PubMed  CAS  Google Scholar 

  33. Castells A, Bruix J, Bru C, et al.: Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109:917–922.

    Article  PubMed  CAS  Google Scholar 

  34. Kouroumalis E, Skordilis P, Thermos K, et al.: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42:442–447.

    Article  PubMed  CAS  Google Scholar 

  35. Okuda K, Ohtuski T, Obata H, et al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985, 56:918–928. The study generated the Okuda clinical staging criteria.

    Article  PubMed  CAS  Google Scholar 

  36. Bruix J, Castells A, Bosch J, et al.: Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111:1018–1022.

    Article  PubMed  CAS  Google Scholar 

  37. Rust C, Gores G: Locoregional management of hepatocllular carcinoma. Surgical and ablation therapies. Clin Liver Dis 2001, 5:161–173.

    Article  PubMed  CAS  Google Scholar 

  38. Mor E, Kaspa R, Sheiner P, et al.: Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998, 129:643–653.

    PubMed  CAS  Google Scholar 

  39. Nagao T, Inoue S, Gotos S, et al.: Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg 1987, 205:33–40.

    Article  PubMed  CAS  Google Scholar 

  40. Sarasin F, Giostra E, Mentha G, et al.: Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness analysis. Hepatology 1998, 28:436–442. Key reference that addresses the cost-effectiveness of liver resection versus liver transplantation as first-line therapy for small, localized tumors.

    Article  PubMed  CAS  Google Scholar 

  41. Bruix J: Treatment of hepatocellular carcinoma. Hepatology 1997, 25:259–262.

    Article  PubMed  CAS  Google Scholar 

  42. Majno P, Sarasin F, Mentha G, et al.: Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000, 31:899–906.

    Article  PubMed  CAS  Google Scholar 

  43. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693–699. Frequently cited study on liver transplantation as the primary treatment modality for HCC. The Milan criteria for HCC size and number (single tumor less than 5 cm wide or three or less lesions of less than or equal to 3 cm wide) are used to determine if a patient is an appropriate candidate for liver transplantation.

    Article  PubMed  CAS  Google Scholar 

  44. Yao F, Ferrell L, Bass N, et al.: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394–1403.

    Article  PubMed  CAS  Google Scholar 

  45. Figueras J, Jaurrieta E, Valis C, et al.: Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997, 25:1485–1489.

    Article  PubMed  CAS  Google Scholar 

  46. Llovet J, Bruix J, Fuster J, et al.: Liver transplantation for small hepatocellular carcinoma: the Tumor-Node-Metastasis classification does not have prognostic power. Hepatology 1998, 27:1572–1577.

    Article  PubMed  CAS  Google Scholar 

  47. International Union Against Cancer (IUAC) Sobin LH, Wittekind C, eds: TNM classification of malignant tumors. Edn 5. John Wiley and Sons: New York; 1997: 74–77.

    Google Scholar 

  48. Llovet J, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434–1440.

    Article  PubMed  CAS  Google Scholar 

  49. Groupe d’Etude et de Traitament du carcinoma hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995, 332:1294–1296.

    Article  Google Scholar 

  50. Bruix J, Llovet J, Castells A, et al.: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998, 27:1578–1583.

    Article  PubMed  CAS  Google Scholar 

  51. Llovet J, Vilana R, Bru C, et al.: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124–1129.

    Article  PubMed  CAS  Google Scholar 

  52. Vilana R, Brui J, Bru C, et al.: Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992, 16:353–357.

    Article  PubMed  CAS  Google Scholar 

  53. Castells A, Bruix J, Bru C, et al.: Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993, 18:1121–1126.

    PubMed  CAS  Google Scholar 

  54. Livraghi T, Goldberg S, Lazzaroni S, et al.: Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999, 210:655–661.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of California, San Francisco, S357, 513 Parnassus Avenue, 94143-0538, San Francisco, CA, USA

    Francis Yao MD & Norah Terrault MD, MPH

Authors
  1. Francis Yao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norah Terrault MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yao, F., Terrault, N. Hepatitis C and hepatocellular carcinoma. Curr. Treat. Options in Oncol. 2, 473–483 (2001). https://doi.org/10.1007/s11864-001-0069-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0069-6

Keywords

Search

Navigation